ArticleNutrition reviews2026
Omega-3 Polyunsaturated Fatty Acids and Adipose Tissue Inflammation in Humans: A Scoping Review.
Article in Nutrition reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Omega-3 PUFAs Mitigate Polytrauma-Induced Gut-Liver-Lung Inflammation and Organ Dysfunction via GPR120/PPAR-γ.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Adipose tissue (AT) inflammation is a topic of increasing interest given its role in initiating systemic subclinical inflammation. Evidence from preclinical studies suggests that n-3 polyunsaturated fatty acids (PUFAs) may ameliorate AT inflammation through various pathways. However, fewer data are available from humans, and existing studies are heterogeneous in design and findings. The objective of this scoping review was to identify, review, and map the current literature on the relationship between n-3 PUFAs and AT inflammation in healthy humans. MEDLINE, EMBASE, and Cochrane databases were searched from inception to August 4, 2022. Eligible studies included experimental trials and observational studies, enrolling nonpregnant adult study populations free of diagnosed chronic/infectious diseases. Screening and data extraction were performed on study characteristics. Overall, the 25 retained studies were heterogeneous in study design, intervention formulation/exposure assessment, comparator, study duration, and methods used to characterize AT inflammation. Most experimental trials used EPA+DHA [eicosapentaenoic acid (EPA, 20:5n-3) and docosapentaenoic acid (DPA, 22:5n-3)] supplementation and measured circulating adiponectin and leptin to characterize AT inflammation. A wide range of comparators were employed, including saturated/unsaturated oils, ketogenic diets, and n-6 PUFAs. All observational studies reported a significant association with ≥1 of their primary outcomes, while 15 of 20 experimental trials documented a significant effect of n-3 supplementation on ≥1 outcomes. Existing human literature on n-3 PUFAs and AT inflammation is inconclusive due to the limited number of studies available and their heterogeneous designs. Therefore, larger, longer-term longitudinal studies and experimental trials using AT biopsy measures or validated AT-specific biomarkers are needed. Registration: Open Science Framework (https://doi.org/10.17605/OSF.IO/29WGQ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.